Nephrology News
Axitinib-Pembrolizumab Combo Promising for Advanced RCC
In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/